The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib
Cachexia commonly occurs at the terminal stage of cancer and has largely unclear molecular mechanisms.A recent study published in Nature Medicine,entitled '